ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0833

Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA

Timothy Wilson1, Claudia Lugo2, Marie Feser3, Mark Gillespie4, Troy Torgerson5, Gary Firestein6, V. Michael Holers7, Kevin Deane8 and Kristen Demoruelle9, 1Thomas Jefferson University, Philadelphia, PA, 2University of Colorado, Denver, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO, 4Allen Institute for Immunology, Seattle, WA, 5Allen Institute for Immunology, Enumclaw, WA, 6University of California, San Diego, San Diego, CA, 7University of Colorado Anschutz Medical Campus, Aurora, 8University of Colorado Denver Anschutz Medical Campus, Aurora, CO, 9University of Colorado Anschutz Medical Campus, Golden, CO

Meeting: ACR Convergence 2025

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Biomarkers, rheumatoid arthritis, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes II: Look What You Made Me Do (Prediction) (0831–0836)

Session Type: Abstract Session

Session Time: 3:30PM-3:45PM

Background/Purpose: The presence of serum anti-CCP-IgG antibodies can predict the future development of clinically evident RA. Neutrophil extracellular trap (NET) formation can be a source of extracellular citrullinated (cit) proteins that can be antigenic targets of anti-CCP. Our group previously reported increased NET formation of sputum neutrophils from the lungs of individuals with RA and at-risk for RA that correlated with sputum anti-CCP levels. The objective of this study was to evaluate the relationship between sputum anti-CCP, sputum NET-associated proteins, and the risk and timing of transitions from an ‘at-risk’ state of systemic autoimmunity to clinical RA.

Methods: We included 98 individuals who were serum anti-CCP-IgG(+) (CCP3, Werfen), without examination evidence of inflammatory arthritis (IA) at baseline, had at least one follow-up visit with a joint examination, and had a baseline induced sputum sample. Nineteen individuals (19.4%) met 2010 ACR/EULAR classification criteria for RA (Classified RA) and 71 (72.4%) did not develop RA after at least 12 months of follow-up. There were 8 individuals who developed unclassifiable IA and were excluded from this analysis. Baseline sputum cell-free supernatant was tested by ELISA for anti-CCP-IgG (CCP3) and anti-CCP-IgA (CCP3.1 plate with research modification to detect IgA only). In a subset with adequate sample remaining, sputum supernatant was tested by immunoassays for NET-associated proteins, including calprotectin (Werfen), extracellular DNA (exDNA, Invitrogen), extracellular neutrophil elastase (exNE, Invitrogen), nucleosomes (Nu.Q H3.1, Volition) and cit-nucleosomes (Nu.Q H3R8Cit, Volition).

Results: Baseline sputum anti-CCP levels were higher in individuals who later transitioned to Classified RA compared to those who did not develop RA (anti-CCP-IgA, p< 0.001; anti-CCP-IgG, p=0.003, Table 1, Figure 1A-B). Sputum nucleosome and cit-nucleosome levels were also higher in individuals who transitioned to RA (Table 1, Figure 1C-D), but were not independently associated after adjusting for sputum anti-CCP-IgA level. Within individuals who transitioned to RA, sputum calprotectin and exNE levels correlated with time to RA onset (Figure 2A-B), with lower levels in those who developed RA within 12 months (Figure 2C-D). Sputum anti-CCP-IgA, exDNA, nucleosome, and cit-nucleosome and plasma calprotectin levels did not correlate with time to RA onset (p >0.05).

Conclusion: We found that anti-CCP and NET-associated nucleosomes in the sputum are increased in serum anti-CCP3+ individuals who transitioned to Classified RA. Sputum NET-associated proteins calprotectin and exNE correlated with time to RA onset, though surprisingly were lower in the 12 months preceding RA onset. These data support an important role of lung immunobiology and NETosis in transitions from systemic autoimmunity to RA and identify sputum biomarkers that can enhance prediction and timing of RA. Longitudinal studies are needed to determine whether decreasing sputum calprotectin and exNE levels result from enhanced local clearance and whether this process plays a role in imminent RA onset.

Supporting image 1

Supporting image 2Figure 1. Sputum anti-CCP and nucleosome levels in individuals at-risk for RA. The figure depicts baseline sputum anti-CCP-IgA (Panel A), sputum anti-CCP-IgG, (Panel B), sputum nucleosome (Panel C) and sputum citrullinated nucleosome (cit-nucleosome, Panel D) in serum anti-CCP-IgG positive individuals who did vs. did not develop Classified RA during follow-up. P-values calculated by Wilcoxon rank sum test.

Supporting image 3Figure 2. Sputum calprotectin and extracellular neutrophil elastase (exNE) levels associated with timing of RA onset. In serum anti-CCP-IgG positive individuals who developed Classified RA within 36 months of follow-up, the figure depicts correlations between time to RA onset (in months from baseline visit) and baseline sputum calprotectin (Panels A) or sputum exNE (Panels B). P-values by Spearman’s correlation. Baseline sputum calprotectin (Panel C) and sputum exNE (Panel D) levels are compared between individuals who developed Classified RA in 0-12 months vs. 13-36 months after baseline sputum. P-values calculated by Wilcoxon rank sum test.


Disclosures: T. Wilson: None; C. Lugo: None; M. Feser: None; M. Gillespie: Novo Nordisk, 11, Omeros, 11; T. Torgerson: Eli Lilly, 2, Pharming Healthcare, 2, Takeda, 2; G. Firestein: Eli Lilly, 5; V. Holers: Q32 Bio, 12,, 2; K. Deane: Inova Diagnostics, 1; K. Demoruelle: Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Gilead, 5, Merck/MSD, 2, Pfizer, 5.

To cite this abstract in AMA style:

Wilson T, Lugo C, Feser M, Gillespie M, Torgerson T, Firestein G, Holers V, Deane K, Demoruelle K. Sputum Anti-CCP-IgA and NET-Associated Proteins Predict Risk and Timing of the Transition From Systemic Autoimmunity to Classified RA [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/sputum-anti-ccp-iga-and-net-associated-proteins-predict-risk-and-timing-of-the-transition-from-systemic-autoimmunity-to-classified-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sputum-anti-ccp-iga-and-net-associated-proteins-predict-risk-and-timing-of-the-transition-from-systemic-autoimmunity-to-classified-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology